Children and adolescents with sickle cell anemia who received the adenosine diphosphate–directed antiplatelet agent prasugrel had no significant reduction in painful vasoocclusive crises compared with those who received placebo, found a trial conducted in 13 countries (Heeney MM et al. N Engl J Med. doi:10.1056/NEJMoa1512021 [published online December 8, 2015]). Previous studies had suggested that prasugrel reduced markers of platelet activation and, consequently, the rate and intensity of vasoocclusive pain in sickle cell anemia.
Slomski A. Antiplatelet Drug Doesn’t Reduce Pain of Sickle Cell Anemia. JAMA. 2016;315(8):742. doi:10.1001/jama.2016.1081